In a phase II trial involving 37 patients diagnosed with asymptomatic BMs in NSCLC, only a minority (29.7%) of individuals with PD-L1-positive NSCLC exhibited a favorable response in terms of BMs (11). This evidence concerns the gene CD274 and non-small cell lung carcinoma.